In your role, how do you help advance life sciences research and development?

I focus on helping clients navigate and overcome their growth challenges in the drug discovery and life science sectors. Clients typically come to us with specific problems related to expanding their market presence or improving their operational efficiencies. My role involves analyzing these issues to offer actionable insights and strategic advice that can help drive their business forward. We aim to convert complex market data into understandable and executable strategies for our clients, ensuring they can achieve sustainable growth despite the industry's dynamic nature.

What do you see as the single biggest issue holding back drug discovery today?

In my opinion, the core issue is that most drug discovery teams overlook the significance of data, making it a secondary consideration in their decision-making process. Everyone wants to focus on building a solution that does everything. It does the molecular modeling, it does the prediction, and it will help you reach your endpoints. But is it optimal for the drug developer and, most importantly, the patient? You must focus on the data that's working behind the scenes, which is a critical oversight. I think companies need to go back and reassess the quality of the underlying data as a first step toward solidifying their data infrastructure, which requires thorough evaluation and curation of all their datasets.

What is the significance of establishing a solid data foundation for drug discovery?

Recent shifts in our research focus underscore how crucial high-quality data is in the drug discovery process. Previously, the emphasis was predominantly on the drug target itself. However, the industry has realized that 'garbage in, garbage out' holds particularly true; the quality of your data fundamentally determines the output's quality. The challenge is effectively integrating diverse and often siloed data sets while simultaneously verifying the quality of that data to enhance drug discovery outcomes.

Are you hopeful that organizations can collaborate to solve some of the industry's biggest data challenges?

I am very hopeful! But, I think this starts with individual organizations increasing investment in building thought leadership around data management. Many organizations do not sufficiently focus on the data they collect, particularly data sourced from public domains, which is a critical area for improvement. The next step would be enhancing cross-collaboration between organizations, as this could greatly benefit the industry as a whole.

What common challenges do you see in the industry regarding data management?

The overall drug discovery process faces multifaceted challenges due to the increasing complexity and array of data types. Integrating biological data such as bioactivity, proteomic, and pharmacodynamic data is crucial for making informed decisions rapidly, a necessity underscored by recent global health crises such as the COVID-19 pandemic. These situations have heightened the urgency for quickly developing and approving new drugs to get them from the laboratory to the bedside without delay.

How do organizational structures impact the efficiency of information sharing and data management?

Traditional organizational structures in pharmaceutical companies, often characterized by hierarchical and siloed departments, can significantly impede the flow of information and collaboration. These structures are particularly problematic in the context of modern drug discovery, where a multidisciplinary approach is essential. The isolation of departments leads to duplicated efforts and prevents effective sharing of insights and data across different teams, resulting in missed opportunities for synergy and increased inefficiencies.

Are there broader implications for data management inefficiencies within drug discovery teams?

These inefficiencies can drastically inhibit a team's ability to respond to new information and adapt strategies accordingly. This can delay the development cycle and increase the time-to-market for new drugs. Beyond just slowing down processes, these inefficiencies can lead to significant financial losses, as delayed projects mean missed market opportunities and diminished returns on investment.

Where do you think AI can have the most impact, and what are some of the potential pitfalls?

Adopting and adapting to innovative computational techniques, particularly platforms incorporating AI and machine learning, is becoming increasingly critical. These technologies can handle large datasets with greater efficiency and enhance the accuracy of predicting outcomes, streamlining the entire drug development pipeline. AI, for instance, significantly boosts early-stage drug discovery by improving the prediction of drug-target interactions and optimizing the selection of promising leads.

In such a complex environment, do you have any general solutions for how companies can overcome these challenges?

The rapid changes in the drug discovery landscape necessitate that companies adopt new technologies and continuously evolve their business models and operational strategies to maintain competitiveness. Implementing advanced data sourcing, analytics, and management systems is crucial in this context. Equally important is fostering a culture that embraces change and promotes data literacy within organizations.

If you had a magic wand to change anything in the drug discovery process, what would you change?

If I could introduce one major improvement in the drug discovery field, it would be the enhanced integration of software tools. Many laboratories and research facilities currently use multiple platforms that do not effectively communicate with one another, leading to inefficiencies and delays in the discovery process. By improving interoperability between these tools, we could significantly accelerate the development of new therapies and enhance the overall effectiveness of the drug discovery process.

データの優先順位付けは、どのように創薬を加速させるのか？

私たちはFrost & Sullivanのヘルスケア・ライフサイエンス部門のプリンシパルコンサルタントであるZoheb Hassan博士に、現在の創薬状況を定義する複雑さについてお話を伺いました。博士の視点は、増え続ける膨大なデータを管理・パッケージ化し、実用的な洞察へと変換する難しさ、そして創薬が進まない主な原因として「データの優先順位付け不足」を強調しています。

CAS：あなたの役割において、どのようにライフサイエンス分野の研究開発を推進していますか？

CAS：現在、創薬を阻んでいる最大の問題は何だとお考えですか？

CAS：創薬のための強固なデータ基盤を確立することの意義は何でしょうか？

CAS：組織が協力して業界最大のデータ課題を解決できると期待していますか？

CAS：データ管理に関して、業界ではどのような共通の課題がありますか？

CAS：組織構造は情報共有とデータ管理の効率にどのように影響を与えるのでしょうか？

CAS: 創薬チーム内のデータ管理の非効率性には、より広範な影響があるのでしょうか？

CAS: AI が最も大きな影響を与える可能性があるのはどの分野だとお考えですか。また、潜在的な落とし穴にはどのようなものがありますか。

CAS：このような複雑な環境で、企業がこれらの課題を克服するための一般的なソリューションはありますか？

CAS：創薬プロセスにおいて何かを変えられる魔法の杖があるとしたら、何を変えますか？

Zoheb Hassan博士過去8年間にわたり、ヘルスケアおよびライフサイエンス分野を専門とする成長戦略コンサルタントとして活躍しています。市場データや研究成果を実用的な洞察に変換し、クライアントが新たなトレンドや脅威、最新技術に影響される絶えず変化する環境に対応できるよう支援しています。博士の専門知識は、クライアントが競合他社より一歩先を行き、市場の変化を成長機会として捉えられるようにすることに貢献しています。コンサルティングに従事する前は、キングスカレッジロンドンで生物医学を専攻し、糖尿病研究とGPCRの薬物標的化をテーマにB.Sc.、M.Sc.、Ph.D.を取得しています。